Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

NAL HIGHLIGHTS

On September 10, 2008, Vanda met with the U.S. Food and Drug Administration (FDA) to discuss the not-approvable action letter that the FDA issued to Vanda on July 25, 2008 regarding iloperidone. The FDA asked Vanda to provide a complete response to the not-approvable letter highlighting arguments made during the meeting. Vanda expects to submit the complete response within the next few weeks. The timing or outcome of any FDA review of the response is uncertain at this time.

Vanda has suspended all commercial and development activities pending further review. Vanda has also reduced its cash burn and is reviewing a number of options to further reduce expenses and cash burn.

FINANCIAL DETAILS

Operating Expenses. Third quarter 2008 R&D expenses, primarily consisting of salaries and related costs of R&D personnel, stock-based compensation, and the costs of consultants, materials and supplies associated with clinical trials and research initiatives, totaled $3.8 million, compared to $5.5 million in the second quarter of 2008 and $13.9 million in the third quarter of 2007. The decrease in R&D expenses in the third quarter of 2008 relative to the second quarter of 2008 is primarily attributable to lower costs in the Phase III tasimelteon chronic primary insomnia clinical trial for which Vanda reported top-line results in June of 2008. The decrease in R&D expenses in the third quarter of 2008 relative to the third quarter of 2007 is primarily attributable to lower clinical trial costs in the third quarter of 2008 compared to the costs from trials conducted in the third quarter of 2007 and the $5.0 million milestone charge recorded in the third quarter of 2007 resulting from the submission of the NDA for iloperidone.

-- General and administrative (G&A) expenses totaled $7.4 million in the third quarter of 2008, compared to $8.5 million in the second quarter of 2008 and $9.6 million in the third quarter of 2007. The decrease in
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
(Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 Called ... reducing and eliminating several types of pediatric brain ... been achieved in over 30 years of research ... Light Foundation, proves that one mom's determination can ... just before Halloween trick-or-treating, and it’s only fitting ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... BioMarin,Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... a company,update at the Credit Suisse 2008 Annual Healthcare ... 10:30 a.m. MST., Interested parties may access a ... section of the BioMarin website, http://www.BMRN.com .,A replay ...
... Stock Exchange Symbol: MS, EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - ... of multiple sclerosis (MS), today,announced that Mr. Kevin Giese, President ... Healthcare Conference in New York., WHEN: ... WHERE: New York Palace Hotel, New York., ...
... that management will present at the following,investor conferences in November., ... New York Palace Hotel Wednesday, November 12, 2008 ... Conference The St. Regis Hotel, New York Tuesday, ... will be audio webcast live and available for replay,from Dendreon,s ...
Cached Biology Technology:BioMarin to Present at the Credit Suisse Healthcare Conference 2BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference 2
(Date:10/29/2014)... of kidney cancer patients in Europe sheds light on ... an apparent link between exposure to aristolochic acid and ... research, by an international team led by scientists from ... Montreal, underscores the importance of investigating possible sources of ... of the Aristolochia genus, also has been suspected of ...
(Date:10/28/2014)... North America, Europe and China have published a paper ... Sciences that reveals important details about key transitions ... From strange and exotic algae, mosses, ferns, trees and ... and vegetables we eat and the ornamental plants adorning ... a billion years of history., "Our study generated DNA ...
(Date:10/28/2014)... a novel environment are linked to individual differences ... study completed at the University of Eastern Finland ... The study used novel, long-term observations of individual ... analyse if behaviours predict the vulnerability to fishing ... hatchery rearing environments. Based on the results, ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3Fish 'personality' linked to vulnerability to angling 2
... have elucidated a key mechanism by which cancer cells ... and raw materials required to sustain runaway growth. ... Ludwig Cancer Research study also reveals how the aggressive ... therapies that should disrupt this capabilityknown as the Warburg ...
... animals will choose to steer clear of dirt but their ... risk of disease as a result. A study of ... near to used nesting material and droppings left by other mice. ... opportunity to eat outweighs an increased risk of disease from other ...
... to learn that individual "molecular muscles" within cells respond to ... cells "feel" the environment and appropriately adapt their shapes and ... 20 in the journal Nature Materials , specifically sheds ... internal signals. A computer model the researchers developed, ...
Cached Biology News:Targeting cancer's sweet tooth 2Targeting cancer's sweet tooth 3Clean living is a luxury wild animals can't afford, study suggests 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3
... station, 100-120 V, is used to coat the ... to create the source of the DNA that ... Helios gene gun. The station includes a tubing ... 12 foot Nalgene nitrogen regulator hose, two 0.1875 ...
... 220-240 V, is used for biolistic particle delivery ... an adjustable helium pulse to sweep DNA-, RNA-, ... wall of a small plastic cartridge directly into ... in situ, in vitro, in vivo, and ex ...
... system, 220-240 V, is used for biolistic ... handheld device employs an adjustable helium pulse ... gold microcarriers from the inner wall of ... cells. This system has a 2 square-centimeter ...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Biology Products: